Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.
Anti-TNF-α biosimilars showed a 91% drug survival rate at 12 months, with no significant differences between infliximab, etanercept, and adalimumab. Long-term effectiveness and safety of anti-TNF-α ...
Dye binds to proteins altered by prostate cancer fo form PSA. Two of the most commonly used classes of medication—statins and nonsteroidal anti-inflammatory drugs (NSAIDs)—may compromise already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results